Copernicus Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Copernicus Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$657K	Buy	6,000 +1,000	+20%	+$104K	7.95%	7
2021 Q2	$468K	Buy	+5,000	New	+$460K	7.38%	6
2020 Q3	–	Sell	-84,626	Closed	-$4.7M	–	24
2020 Q2	$4.7M	Buy	+84,626	New	+$3.62M	5.16%	11
2019 Q2	–	Sell	-66,000	Closed	-$1.74M	–	19
2019 Q1	$1.74M	Buy	+66,000	New	+$1.56M	4.47%	11

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Copernicus Capital Management's HZNP Position: Q3 2021 in Review

Copernicus Capital Management increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 20% in Q3 2021, buying an estimated $104K and bringing the position to 6,000 shares worth $657K. The position accounts for 7.95% of the portfolio, ranked #7.

Copernicus Capital Management first reported a position in HZNP in Q1 2019 and has held it in 4 quarters since. The position peaked at $4.7M in Q2 2020. 572 funds tracked by Wall St. Rank hold HZNP as of Q3 2021.

Copernicus Capital Management held 6,000 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $657K as of Q3 2021.
Copernicus Capital Management bought 1,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2021, an estimated $104K.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 7.95% of Copernicus Capital Management's portfolio in Q3 2021, its #7 holding.
Copernicus Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2019 and has held it in 4 quarters since.
Copernicus Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $4.7M in Q2 2020.
572 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2021.

Based on Copernicus Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.